Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer

Journal of Clinical Oncology

Volumn 19, Issue 20, 2001, Pages 4081-4087

  Stevenson, J P ^a   Redlinger, M ^a   Kluijtmans, L A J ^a   Sun, W ^a   Algazy, K ^a   Giantonio, B ^a   Haller, D G ^a   Hardy, C ^a   Whitehead, A S ^a   O'Dwyer, P J ^a  

^a Medical Arts Bldg   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ATROPINE; DEXAMETHASONE; GRANISETRON; HOMOCYSTEINE; IRINOTECAN; LOPERAMIDE; ONDANSETRON; PROCHLORPERAZINE; RALTITREXED;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DIARRHEA; DIGESTIVE SYSTEM CANCER; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG INFUSION; DRUG POTENTIATION; DRUG TOLERABILITY; FATIGUE; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LIVER FUNCTION; MALE; NEUTROPENIA; PHARMACOGENETICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR;

EID: 0035886707     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.20.4081     Document Type: Article

References (38)

1. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer
2. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer
3. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix
4. Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer
5. Irinotecan therapy in adults with recurrent or progressive malignant glioma
6. Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines
7. Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro
8. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer
9. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial
10. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer: Tomudex Colorectal Cancer Study Group
11. Combination of raltitrexed with other cytotoxic agents: Rationale and preclinical observations
12. A Phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumors
13. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines
14. Functional folate status as a prognostic indicator of toxicity in clinical trials of the multitargeted antifolate LY231514
15. Folate/vitamin B12 inter-relationships
16. Thermolabile methylenetetrahydrofolate reductase in patients with coronary artery disease
17. Human methylenetetrahydrofolate reductase: Isolation of cDNA, mapping and mutation identification
18. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase
19. Worldwide distribution of a common methylenetetrahydrofolate reductase mutation
20. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations
21. The common thermolabile variant of methylene-tetrahydrofolate reductase is a major determinant of mild hyperhomocysteinemia
22. Correlation of a common mutation in the methylenetetrahydrofolate reductase gene with plasma homocysteine in patients with premature coronary artery disease
23. A common mutation in the methylenetetrahydrofolate reductase gene is associated with an accumulation of formylated tetrahydrofolates in red blood cells
24. Reporting results of cancer treatment
25. A simple salting out procedure for extracting DNA from human nucleated cells
26. Accurate and rapid "multiplex heteroduplexing" method for genotyping key enzymes involved in folate/homocysteine metabolism
27. Phase I study of irinotecan and raltitrexed in patients with advanced gastrointestinal tract adenocarcinoma
28. Familial deficiency of dihydropyrimidine dehydrogenase: Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity
29. Schedule-dependent enhancement of the cytotoxicity of fluoropyrimidines to human carcinoma cells in the presence of folinic acid
30. MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil
31. Pharmacogenetics in cancer chemotherapy: 677C→T methylenetetra-hydrofolate reductase (MTHFR) gene polymorphism and toxicity after cyclophosphamide, methotrexate, and 5-fluorouracil (CMF)
32. Folate deficiency in rats induces DNA strand breaks and hypomethylation within the p53 tumor suppressor gene
33. Genomic DNA methylation decreases in response to moderate folate depletion in elderly women
34. Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer
35. Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults
36. Germ line polymorphisms in cytochrome-P450 1A1 (C4887 CYP 1A1) and methylenetetrahydrofolate reductase (MTHFR) genes and endometrial cancer susceptibility
37. Loss of heterozygosity at the 5,10-methylenetetrahydrofolate reductase locus in human ovarian carcinomas
38. Loss of heterozygosity of methylenetetrahydrofolate reductase in colon carcinomas